Entrepreneur's University Forum: Reimbursement Strategies and the Business Model

Friday, March 22 2013
8:00 am – 10:00 am

Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA

For emerging companies seeking financing and strategic partnerships, it is important to understand the payer and government reimbursement strategy and how that reinforces a financeable business model. Too many emerging companies are so enamored with their science but they ignore the important fundamental question: who will pay for it? We would like you to offer perspectives and commentary on that quandary.  Our speakers have a broad range of experiences covering all aspects of the life cycle of a successful life science or med device company, from venture financing, business and regulatory strategy, product adoption and pricing, strategic alliances and collaborations, to research and development.


  • Nico Lewine, Consultant at Health Advances
  • Mark Speers, Founder, Partner and Managing Director at Health Advances
  • Mark Tepper, PhD, CEO, JB Therapeutics


Speaker Bios:

Nico Lewine, Consultant at Health Advances, works with a wide variety of clients spanning the pharma, biotech, medical device, and diagnostics industries. As Chair of Health Advances’ internal Committee on Reimbursement and Health Policy, Nico’s work usually focuses on helping clients navigate the reimbursement landscape in order to achieve premium pricing and strong market penetration.  Nico often participates in national forums with leaders from payers, major hospital systems, and other constituencies.

Mark Speers is the founder, Partner and Managing Director at Health Advances. At Health Advances, Mark works extensively with clients to evaluate the commercial potential and develop market launch strategies for new medical devices and diagnostics. He also offers expertise in mergers and acquisitions work for strategic and financial buyers, having now contributed to over $30 billion in client transactions. Mark has been advising senior medtech executives for 30 years.

Mark Tepper is an experienced entrepreneur & C-level biotech professional that works on identifying and commercializing early stage therapeutics and drug discovery assets. His specialty is identifying disruptive technologies and building a commercial plan and team around them. Over the last 10 years, Dr. Tepper helped launch 5 biotechnology companies, and contributed directly to an additional 4 others. His successes have included RXi Pharmaceuticals (fka Araios, Inc.) which he founded in 2003 and served as President from 2003-2007 and NKT Therapeutics which he founded in 2008 and raised $8M in a series A round. He is currently working on 2 Newcos; one in the fibrotic disease space, and one on unique monoclonal antibodies to co-stimulatory molecules. On the technical and management side he spent 15 years at Serono and BMS, where he led drug discovery and development programs of up to 120 employees and annual budgets of up to ~$20M. Over the years he played key roles as part of a larger drug development team that gained approval of 5 marketed Pharmaceutical products (Deoxyspergualin, Taxol, Rebif, Orcenia and Gonal-F). He is an expert in a broad array of cutting-edge drug discovery technologies and has extensive experience in drug development in the fields of immunology, inflammation, transplantation, autoimmune diseases, endocrinology, metabolic diseases, oncology, and pain.        

Share MassBio